Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study

NCT04560231 is registered in ClinicalTrials.gov with Lahore General Hospital as lead sponsor.

NCT NCT04560231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study
Lead sponsor
Lahore General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
June 1, 2020
Completion date
November 30, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov infection